Literature DB >> 21893636

Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome.

Frank Moosig, Wolfgang Ludwig Gross, Kristina Herrmann, Jan Phillip Bremer, Bernhard Hellmich.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21893636     DOI： 10.7326/0003-4819-155-5-201109060-00026

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  57 in total

Review 1.  [Childhood vasculitis].

Authors:  J B Kümmerle-Deschner; J Thomas; S M Benseler
Journal:  Z Rheumatol       Date:  2015-12       Impact factor: 1.372

2.  [ANCA-associated vasculitis].

Authors:  J U Holle
Journal:  Z Rheumatol       Date:  2013-06       Impact factor: 1.372

Review 3.  New-generation therapy for ANCA-associated vasculitis.

Authors:  David Jayne
Journal:  Clin Exp Nephrol       Date:  2013-09-07       Impact factor: 2.801

4.  Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.

Authors:  Jonathan Steinfeld; Eric S Bradford; Judith Brown; Stephen Mallett; Steven W Yancey; Praveen Akuthota; Maria C Cid; Gerald J Gleich; David Jayne; Paneez Khoury; Carol A Langford; Peter A Merkel; Frank Moosig; Ulrich Specks; Peter F Weller; Michael E Wechsler
Journal:  J Allergy Clin Immunol       Date:  2018-12-19       Impact factor: 10.793

Review 5.  Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.

Authors:  G A Ramirez; N Maugeri; M G Sabbadini; P Rovere-Querini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

Review 6.  Key advances in the clinical approach to ANCA-associated vasculitis.

Authors:  Cees G M Kallenberg
Journal:  Nat Rev Rheumatol       Date:  2014-07-01       Impact factor: 20.543

7.  [ANCA-associated vasculitis].

Authors:  J U Holle
Journal:  Internist (Berl)       Date:  2015-01       Impact factor: 0.743

Review 8.  Biologic therapies targeting eosinophils: current status and future prospects.

Authors:  Fanny Legrand; Amy D Klion
Journal:  J Allergy Clin Immunol Pract       Date:  2015 Mar-Apr

9.  Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.

Authors:  Michael E Wechsler; Praveen Akuthota; David Jayne; Paneez Khoury; Amy Klion; Carol A Langford; Peter A Merkel; Frank Moosig; Ulrich Specks; Maria C Cid; Raashid Luqmani; Judith Brown; Stephen Mallett; Richard Philipson; Steve W Yancey; Jonathan Steinfeld; Peter F Weller; Gerald J Gleich
Journal:  N Engl J Med       Date:  2017-05-18       Impact factor: 91.245

10.  Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.

Authors:  Fei Li Kuang; Michael P Fay; JeanAnne Ware; Lauren Wetzler; Nicole Holland-Thomas; Thomas Brown; Hector Ortega; Jonathan Steinfeld; Paneez Khoury; Amy D Klion
Journal:  J Allergy Clin Immunol Pract       Date:  2018-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.